Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT164 mRNA tuberculosis vaccines in healthy adults
NCT05537038Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Apr 2023
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Tuberculosis (TB) comparing BNT164a1, BNT164b1 and Placebo (3 arms). Primary endpoints: Frequency of solicited local reactions at the injection site at 7 days, Frequency of solicited systemic reactions at 7 days and 4 more. Started Apr 2023; status: completed.
02
Drugs
BNT164a1BNT164b1
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05537038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537038.